Caris Life Sciences Inc 's Comment on Competition and Industry Peers
The precision oncology industry includes multiple companies providing genomic profiling and sequencing services across various applications. In tissue-based molecular profiling, key competitors are Foundation Medicine (Roche), Tempus, Memorial Sloan Kettering Cancer Center, and New York Presbyterian—Weill Cornell. Blood-based early detection services are offered by Grail, Freenome, Guardant Health, Exact Sciences, and Delfi Diagnostics. For blood-based molecular profiling aimed at therapy selection, competitors include Guardant Health, Tempus, and Foundation Medicine (Roche). Blood-based molecular profiling for minimal residual disease (MRD) tracking and treatment monitoring involves companies such as Natera, Guardant Health, SAGA Diagnostics, Personalis, BillionToOne, Quest Diagnostics, and Adaptive Biotechnologies. Core biopharma services are provided by Foundation Medicine (Roche), Guardant Health, Tempus, Natera, and Personalis. Genomic data and artificial intelligence services are offered by Tempus and Foundation Medicine (Roche). Additional companies operating in the precision oncology testing sector include Illumina.
Sources:
Caris Life Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Caris Life Sciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
